SWITCHING from intravenous (IV) to subcutaneous (SC) vedolizumab was associated with sustained disease control and acceptable treatment persistence over 48 weeks in adults with inflammatory bowel disease (IBD), according to findings from a real-world study.
The single-centre, retrospective cohort study investigated the effectiveness and safety of transitioning patients established on IV vedolizumab to SC maintenance therapy. Although SC administration offers practical advantages, evidence regarding longer-term outcomes following this switch remains limited.
Assessing Subcutaneous Vedolizumab in IBD
The study included 24 adults with IBD who transitioned from IV to SC vedolizumab between August 2020 and October 2023. The cohort comprised 10 patients with Crohn’s disease, 12 with ulcerative colitis, and two with indeterminate IBD.
Researchers assessed clinical disease activity using the Simple Clinical Colitis Activity Index and Harvey-Bradshaw Index, alongside biochemical markers, including C-reactive protein and faecal calprotectin. Treatment persistence was also evaluated at weeks 12, 24, and 48 following the switch.
Treatment Persistence and Disease Activity
Treatment persistence declined over the 48-week follow-up period, from 100% at week 12 to 92% at week 24 and 71% at week 48. Overall, seven patients (29.2%) discontinued SC vedolizumab, with loss of response representing the most frequent reason for discontinuation (n=4).
Among patients who continued treatment, clinical and biochemical disease activity remained stable throughout follow-up. Median faecal calprotectin concentrations were also unchanged across the assessed timepoints, suggesting that disease control was maintained following the transition to SC administration.
Safety and Clinical Implications
The safety findings were also encouraging, with no serious adverse events or systemic hypersensitivity reactions documented during the study. However, one patient experienced an injection-site reaction that prompted a return to IV vedolizumab.
The findings suggest that transitioning from IV to SC vedolizumab can offer an effective maintenance option for appropriately selected adults with IBD. In particular, patients who are in remission when switching may be more suitable candidates for this approach.
However, the small cohort size and retrospective, single-centre design warrant caution when interpreting the findings. Further evidence would help clarify longer-term outcomes and identify which patients are most likely to maintain treatment response following the transition.
Reference
Salehi O et al. Switching from IV to SC vedolizumab in IBD: real-world effectiveness and safety over 48 weeks. npj Autoimmun. 2026;1:8.